5 results about "Apoptosis Inhibitor" patented technology

The present invention relates to a composition comprising a nucleic acid encoding a human-derived survivin polypeptide comprising at least three mutations compared to a natural human-derived survivin polypeptide, said composition being capable of eliciting a tumor-specific humoral or cellular immune response.

The present invention addresses the problem of providing a culture medium for long-term culture of hepatocytes while maintaining the bile canaliculi thereof. The present invention relates to a medium for culturing hepatocytes while maintaining the bile canaliculi that contains, as an active ingredient, one or more selected from the group consisting of AMPK activators, Epac activators, apoptosis inhibitors, and antioxidants, and to a method for maintaining the bile canaliculi that includes culturing hepatocytes using the medium.

This invention belongs to the fields of biotechnology and precision oncology, and discloses a serum-free amplification method for circulating tumor cells (CTCs) based on apoptosis selectivity, along with a dedicated culture medium. This addresses the problems of existing CTC technologies, which rely on physical capture leading to impaired cell viability and low culture success rates. The invention involves mild density gradient centrifugation and erythrocyte lysis of anticoagulated whole blood from patients to obtain a mixed population of leukocytes containing CTCs. This population is then seeded into a serum-free, selective apoptosis medium for three-dimensional culture. The medium contains apoptosis inhibitors and specific growth factors. Utilizing the difference between tumor cells' anti-apoptosis and normal blood cells' susceptibility to apoptosis, leukocyte apoptosis is induced within 4-7 days, while simultaneously supporting CTC survival, adhesion, and clonal proliferation, enabling the amplification of individual CTCs into cell clusters. This method preserves the original activity and heterogeneity of CTCs, is simple to operate, and has good reproducibility, providing a highly active cell source for CTC molecular identification, drug sensitivity testing, and metastasis mechanism research.

This invention relates to the field of pharmaceutical technology, specifically to an engineered long-acting platelet delivery system for loading therapeutic drugs, its preparation method, and its applications. The system comprises platelets loaded with therapeutic drugs and nanoparticles containing platelet apoptosis inhibitors. The engineered long-acting platelet delivery system of this invention enables stable in vitro storage and long-term in vivo circulation. Furthermore, by leveraging the efficient and natural wound tropism and tumor targeting properties of platelets, this system can precisely target residual and circulating tumor cells after surgery, thereby releasing cytotoxic chemotherapeutic drugs and effectively preventing postoperative tumor recurrence and metastasis.

An object of the present invention is to provide a method for producing nerve cells damaged by oxidative stress from a human-derived pluripotent stem cell; a culturing method for cells that allows nerve cells damaged by oxidative stress to be produced from a human-derived pluripotent stem cell; nerve cells damaged by oxidative stress; an evaluation method for a test substance, a screening method for a drug for prevention and / or treatment of a neurodegenerative disease, a screening method for a necroptosis inhibitor, and a screening method for a ferroptosis inhibitor, which use the nerve cells.According to the present invention, there is provided a production method of nerve cells damaged by oxidative stress, the method including a step a of seeding nerve cells obtained by differentiation from a human-derived pluripotent stem cell, at a cell density of 20.0×104 cells / cm2 or less by using a culture medium that substantially does not contain an antioxidant and substantially does not contain an oxidant and a step b of culturing the nerve cells by using the culture medium that substantially does not contain an antioxidant and substantially does not contain an oxidant.